Patients with chronic hypoparathyroidism (hypoPT) experience a significant burden from complications related to decreased serum calcium, increased phosphorus, and absent or deficient PTH. Most importantly, patients with chronic hypoPT managed with conventional therapy of oral calcium and active vitamin D supplementation have adverse kidney outcomes of nephrolithiasis/kidney stones, nephrocalcinosis, and CKD. The advent of evolving approaches to mitigate hypopPT-related kidney complications is a paradigm shift in the management of this rare and highly disabling condition. Led by experts in the field and with the participation of patient advocates, this immersive discussion will highlight the evolution of management approaches toward reducing kidney-related complications and improving quality of life for patients with chronic hypoPT.

This initiative is designed for physicians (endocrinologists, nephrologists, internal medicine specialists, and others) who manage patients with hypoparathyroidism.

Upon completing this activity, learners will have increased knowledge regarding the:

• Patient burden of chronic hypoparathyroidism (hypoPT) despite current treatment approaches
• Evolving approaches to mitigate hypopPT-related kidney complications based on the latest evidence
• Greater competence related to:
  • Implementing management approaches to improve quality of life for patients with chronic hypoPT on conventional treatment

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Medscape. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Dolores Shoback, MD, Program Chair: Professor of Medicine, San Francisco, University of California San Francisco, San Francisco, CA

Suzanne Jan de Beur, MD: Professor of Medicine, University of Virginia School of Medicine, Charlottesville, VA

Patty Keating: Executive Director, HypoPARAthyroidism Association

Michele Rayes: Associate Director, HypoPARAthyroidism Association

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Dolores Shoback, MD: Takeda, Bridge Bio, Consultant; Acendis, Principal Investigator, Consultant; Amolyt, Bone Health Technologies, Principal Investigator.

Suzanne Jan de Beur, MD: American Society of Bone and Mineral Research, Past President, Podcast; XLH Network, Scientific Advisory Board; Current Osteoporosis Reports, Associate Editor; Bone Reports, Editorial Board; Ultragenyx, Researcher, Advisory Board, Coordinating Author, Consulting; Mereo Researcher; Kyowa Kirin, Advisory Board, Researcher, DSMB; NIH, DSMB, PI, Key Personnel, Grant Reviewer; FDA, Grant Reviewer; Calcilytics, Researcher; PCORI, Investigator; Ascendis, Advisory Board

The following faculty reported no relevant financial relationships: 

Patty Keating, Patient; Executive Director, HypoPARAthyroidism Association

Michele Rayes, Patient; Associate Director, HypoPARAthyroidism Association

The following committee member who planned and reviewed content for this activity reported no relevant financial relationships:
Athanasios Bikas, MD 

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Amolyt.